Zullo Joseph A, Nadel Ellen P, Rabadi May M, Baskind Matthew J, Rajdev Maharshi A, Demaree Cameron M, Vasko Radovan, Chugh Savneek S, Lamba Rajat, Goligorsky Michael S, Ratliff Brian B
Departments of Medicine, Pharmacology, and Physiology, Renal Research Institute, New York Medical College, Valhalla, New York, USA; Department of Nephrology and Rheumatology, University Medical Center Goettingen, Goettingen, Germany.
Departments of Medicine, Pharmacology, and Physiology, Renal Research Institute, New York Medical College, Valhalla, New York, USA; Department of Nephrology and Rheumatology, University Medical Center Goettingen, Goettingen, Germany
Stem Cells Transl Med. 2015 Jul;4(7):852-61. doi: 10.5966/sctm.2014-0111. Epub 2015 May 6.
: We previously reported the delivery of endothelial progenitor cells (EPCs) embedded in hyaluronic acid-based (HA)-hydrogels protects renal function during acute kidney injury (AKI) and promotes angiogenesis. We attempted to further ameliorate renal dysfunction by coembedding EPCs with renal mesenchymal stem cells (MSCs), while examining their paracrine influence on cytokine/chemokine release and proinflammatory macrophages. A live/dead assay determined whether EPC-MSC coculturing improved viability during lipopolysaccharide (LPS) treatment, and HA-hydrogel-embedded delivery of cells to LPS-induced AKI mice was assessed for effects on mean arterial pressure (MAP), renal blood flow (RBF), circulating cytokines/chemokines, serum creatinine, proteinuria, and angiogenesis (femoral ligation). Cytokine/chemokine release from embedded stem cells was examined, including effects on macrophage polarization and release of proinflammatory molecules. EPC-MSC coculturing improved stem cell viability during LPS exposure, an effect augmented by MSC hypoxic preconditioning. The delivery of coembedded EPCs with hypoxic preconditioned MSCs to AKI mice demonstrated additive improvement (compared with EPC delivery alone) in medullary RBF and proteinuria, with comparable effects on serum creatinine, MAP, and angiogenesis. Exposure of proinflammatory M1 macrophages to EPC-MSC conditioned medium changed their polarization to anti-inflammatory M2. Incubation of coembedded EPCs-MSCs with macrophages altered their release of cytokines/chemokines, including enhanced release of anti-inflammatory interleukin (IL)-4 and IL-10. EPC-MSC delivery to endotoxemic mice elevated the levels of circulating M2 macrophages and reduced the circulating cytokines/chemokines. In conclusion, coembedding EPCs-MSCs improved their resistance to stress, impelled macrophage polarization from M1 to M2 while altering their cytokine/chemokines release, reduced circulating cytokines/chemokines, and improved renal and vascular function when MSCs were hypoxically preconditioned.
This report provides insight into a new therapeutic approach for treatment of sepsis and provides a new and improved strategy using hydrogels for the delivery of stem cells to treat sepsis and, potentially, other injuries and/or diseases. The delivery of two different stem cell lines (endothelial progenitor cells and mesenchymal stem cells; delivered alone and together) embedded in a protective bioengineered scaffolding (hydrogel) offers many therapeutic benefits for the treatment of sepsis. This study shows how hydrogel-delivered stem cells elicit their effects and how hydrogel embedding enhances the therapeutic efficacy of delivered stem cells. Hydrogel-delivered stem cells influence the components of the overactive immune system during sepsis and work to counterbalance the release of many proinflammatory and prodamage substances from immune cells, thereby improving the associated vascular and kidney damage.
我们之前报道过,嵌入基于透明质酸(HA)的水凝胶中的内皮祖细胞(EPCs)可在急性肾损伤(AKI)期间保护肾功能并促进血管生成。我们试图通过将EPCs与肾间充质干细胞(MSCs)共嵌入来进一步改善肾功能障碍,同时研究它们对细胞因子/趋化因子释放和促炎巨噬细胞的旁分泌影响。活/死检测确定EPC-MSC共培养在脂多糖(LPS)处理期间是否能提高细胞活力,并评估将HA水凝胶包埋的细胞递送至LPS诱导的AKI小鼠对平均动脉压(MAP)、肾血流量(RBF)、循环细胞因子/趋化因子、血清肌酐、蛋白尿和血管生成(股动脉结扎)的影响。检测了包埋干细胞释放的细胞因子/趋化因子,包括对巨噬细胞极化和促炎分子释放的影响。EPC-MSC共培养在LPS暴露期间提高了干细胞活力,MSCs缺氧预处理增强了这种作用。将经缺氧预处理的MSCs与EPCs共包埋后递送至AKI小鼠,在髓质RBF和蛋白尿方面显示出相加性改善(与单独递送EPCs相比),对血清肌酐、MAP和血管生成有类似影响。促炎M1巨噬细胞暴露于EPC-MSC条件培养基后,其极化转变为抗炎M2。将共包埋的EPCs-MSCs与巨噬细胞孵育改变了它们的细胞因子/趋化因子释放,包括抗炎白细胞介素(IL)-4和IL-10释放增加。将EPC-MSCs递送至内毒素血症小鼠可提高循环M2巨噬细胞水平并减少循环细胞因子/趋化因子。总之,当MSCs进行缺氧预处理时,共包埋EPCs-MSCs可提高它们对压力的抵抗力,促使巨噬细胞从M1极化到M2,同时改变它们的细胞因子/趋化因子释放,减少循环细胞因子/趋化因子,并改善肾脏和血管功能。
本报告深入探讨了一种治疗脓毒症的新治疗方法,并提供了一种新的改进策略,即使用水凝胶递送干细胞来治疗脓毒症以及潜在地治疗其他损伤和/或疾病。将两种不同的干细胞系(内皮祖细胞和间充质干细胞;单独和一起递送)嵌入保护性生物工程支架(水凝胶)中,为脓毒症的治疗提供了许多治疗益处。这项研究展示了水凝胶递送的干细胞如何发挥作用以及水凝胶包埋如何增强递送干细胞的治疗效果。水凝胶递送的干细胞在脓毒症期间影响过度活跃的免疫系统的组成部分,并努力平衡免疫细胞释放的许多促炎和促损伤物质,从而改善相关的血管和肾脏损伤。